PRMT8 demonstrates variant-specific expression in cancer cells and correlates with patient survival in breast, ovarian and gastric cancer

Hernandez,Sarah  J.; Dolivo,David  M.; Dominko,Tanja

doi:10.3892/ol.2017.5671

PRMT8 demonstrates variant-specific expression in cancer cells and correlates with patient survival in breast, ovarian and gastric cancer

Authors:
- Sarah J. Hernandez
- David M. Dolivo
- Tanja Dominko
View Affiliations

Affiliations: Department of Biology and Biotechnology, Worcester Polytechnic Institute, Worcester, MA 01605, USA
Published online on: February 1, 2017 https://doi.org/10.3892/ol.2017.5671
Pages: 1983-1989

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent emphasis has been placed on the role of epigenetic regulators and epigenetic marks as biomarkers for cancer diagnosis and prognosis, and as therapeutic targets for treatment. One such class of regulators is the protein arginine methyltransferase (PRMT) family. The present study examined available curated data regarding the expression and alteration of one of the least studied PRMT family members, PRMT8, in various types of cancer and cancer cell lines. Publicly available cancer data on PRMT8 expression were examined using the Human Protein Atlas and the Kaplan‑Meier Plotter, and reverse transcription‑polymerase chain reaction was used to screen a selection of human cell lines for variant‑specific PRMT8 expression. High levels of PRMT8 expression in breast, ovarian and cervical cancer was observed. Additionally, in patients with breast and ovarian cancer, high PRMT8 expression was correlated with increased patient survival, whereas in gastric cancer, high PRMT8 expression was correlated with decreased patient survival. The present study also investigated the expression of PRMT8 variant 2, a novel transcript variant recently identified in our laboratory, in various cancer cell lines. Variant‑specific expression of PRMT8 in numerous distinct cancer cell lines derived from different tissues, including the expression of the novel PRMT8 variant 2 in U87MG glioblastoma cells was demonstrated. The present study proposes the possibility of PRMT8 as a cancer biomarker, based on the high level of PRMT8 expression in various types of cancer, particularly in tissues that would not normally be expected to express PRMT8, and on the correlation of PRMT8 and patient lifespan in several cancer types. Variant‑specific expression of PRMT8 in diverse cancer cell lines suggests the possibility of alternate PRMT8 isoforms to have diverse effects on cancer cell phenotypes.

View Figures

View References

1	Cheung N, Chan L, Thompson A, Cleary ML and So C: Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol. 9:1208–1215. 2007. View Article : Google Scholar : PubMed/NCBI
2	Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, et al: Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer. 128:562–573. 2011. View Article : Google Scholar : PubMed/NCBI
3	Mathioudaki K, Scorilas A, Ardavanis A, Lymberi P, Tsiambas E, Devetzi M, Apostolaki A and Talieri M: Clinical evaluation of PRMT1 gene expression in breast cancer. Tumor Biol. 32:575–582. 2011. View Article : Google Scholar
4	Mathioudaki K, Papadokostopoulou A, Scorilas A, Xynopoulos D, Agnanti N and Talieri M: The PRMT1 gene expression pattern in colon cancer. Br J Cancer. 99:2094–2099. 2008. View Article : Google Scholar : PubMed/NCBI
5	Papadokostopoulou A, Mathioudaki K, Scorilas A, Xynopoulos D, Ardavanis A, Kouroumalis E and Talieri M: Colon cancer and protein arginine methyltransferase 1 gene expression. Anticancer Res. 29:1361–1366. 2009.PubMed/NCBI
6	Li B, Liu L, Li X and Wu L: miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1. Biochem Biophys Res Commun. 464:982–987. 2015. View Article : Google Scholar : PubMed/NCBI
7	Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M and Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 435:1262–1266. 2005. View Article : Google Scholar : PubMed/NCBI
8	Wang H, Huang ZQ, Xia L, Feng Q, Erdjument-Bromage H, Strahl BD, Briggs SD, Allis CD, Wong J, Tempst P and Zhang Y: Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science. 293:853–857. 2001. View Article : Google Scholar : PubMed/NCBI
9	Strahl BD, Briggs SD, Brame CJ, Caldwell JA, Koh SS, Ma H, Cook RG, Shabanowitz J, Hunt DF, Stallcup MR and Allis CD: Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1. Curr Biol. 11:996–1000. 2001. View Article : Google Scholar : PubMed/NCBI
10	Hong H, Kao C, Jeng MH, Eble JN, Koch MO, Gardner TA, Zhang S, Li L, Pan CX, Hu Z, et al: Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer. 101:83–89. 2004. View Article : Google Scholar : PubMed/NCBI
11	Kim YR, Lee BK, Park RY, Nguyen NT, Bae JA, Kwon DD and Jung C: Differential CARM1 expression in prostate and colorectal cancers. BMC Cancer. 10:1972010. View Article : Google Scholar : PubMed/NCBI
12	Pal S, Baiocchi RA, Byrd JC, Grever MR, Jacob ST and Sif S: Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J. 26:3558–3569. 2007. View Article : Google Scholar : PubMed/NCBI
13	Lee J, Sayegh J, Daniel J, Clarke S and Bedford MT: PRMT8, a new membrane-bound tissue-specific member of the protein arginine methyltransferase family. J Biol Chem. 280:32890–32896. 2005. View Article : Google Scholar : PubMed/NCBI
14	Goulet I, Gauvin G, Boisvenue S and Côté J: Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization. J Biol Chem. 282:33009–33021. 2007. View Article : Google Scholar : PubMed/NCBI
15	Zhong J, Cao RX, Zu XY, Hong T, Yang J, Liu L, Xiao XH, Ding WJ, Zhao Q, Liu JH and Wen GB: Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma. FEBS J. 279:316–335. 2012. View Article : Google Scholar : PubMed/NCBI
16	Scorilas A, Black MH, Talieri M and Diamandis EP: Genomic organization, physical mapping, and expression analysis of the human protein arginine methyltransferase 1 gene. Biochem Biophys Res Commun. 278:349–359. 2000. View Article : Google Scholar : PubMed/NCBI
17	Hernandez S and Dominko T: Novel protein arginine methyltransferase 8 isoform is essential for cell proliferation. J Cell Biochem. 117:2056–2066. 2016. View Article : Google Scholar : PubMed/NCBI
18	Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
19	Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
20	Dawson MA and Kouzarides T: Cancer epigenetics: From mechanism to therapy. Cell. 150:12–27. 2012. View Article : Google Scholar : PubMed/NCBI
21	Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar : PubMed/NCBI
22	Kousaka A, Mori Y, Koyama Y, Taneda T, Miyata S and Tohyama M: The distribution and characterization of endogenous protein arginine N-methyltransferase 8 in mouse CNS. Neuroscience. 163:1146–1157. 2009. View Article : Google Scholar : PubMed/NCBI
23	Sammons MA, Zhu J and Berger SL: A chromatin-focused siRNA screen for regulators of p53-dependent transcription. G3 (Bethesda). 6:2671–2678. 2016. View Article : Google Scholar : PubMed/NCBI